Information Provided By:
Fly News Breaks for February 24, 2020
DNLI, SNY, BIIB
Feb 24, 2020 | 07:04 EDT
As previously reported, Jefferies analyst Michael Yee initiated coverage of Denali Therapeutics (DNLI) with a Buy rating and $35 price target. Yee sees "lots of catalysts in 2020" that could move shares of Denali higher, including new Phase I/II data for DNL151 expected mid-year, Phase I/II data mid-20 from DNL747 with Sanofi (SNY), and BBB platform Phase I data for new IDS enzyme replacement by year-end. He also sees a potential "wave of Street enthusiasm in the neuro space" depending on what happens with the FDA and Biogen's (BIIB) aducanumab, telling investors that Denali will be a "clear beneficiary" if the FDA is amenable to a different bar in the huge unmet area of need in Alzheimer's.
News For DNLI;SNY;BIIB From the Last 2 Days
SNY
Jun 5, 2020 | 14:11 EDT
Preliminary research involving 19 patients shows signs that AstraZeneca's (AZN) blood cancer drug Calquence may help hospitalized COVID-19 patients get through the worst of the disease, Reuters reported, citing results in a paper co-authored by the drugmaker's head of oncology research. The executive, Jose Baselga, told Reuters: "These patients were in a very unstable situation, they would have had a dire prognosis ... Within one to three days the majority of these patients got better in terms of ventilation and oxygen needs." Other autoimmune disease drugs that are being tested for their ability to combat the over-reaction of the immune system, known as "cytokine storm," that is seen in severe COVID-19 cases include Regeneron (REGN) and Sanofi's (SNY) Kevzara, Roche's (RHHBY) Actemra and Morphosys (MOR) and GlaxoSmithKline's (GSK) otilimab, the report noted. Reference Link